FilingReader Intelligence

Hile Bio divests, acquires, and navigates shifting market dynamics

June 28, 2025 at 05:01 AM UTC•By FilingReader AI

Shanghai Hile Bio-Technology (SSE:603718) has released its response to the Shanghai Stock Exchange’s regulatory inquiry regarding its 2024 annual report, outlining a year of strategic realignment. Key to this shift was the divestiture of its animal vaccine business by spinning off the loss-making Yangling Jinhai subsidiary, significantly improving the company's balance sheet and profitability.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

Primary Source Document

Special review opinion of Zhongxinghua Certified Public Accountants (Special General Partnership) on the response to the regulatory inquiry letter on information disclosure regarding the 2024 annual report of Shanghai Haili Biotechnology Co., Ltd.June 27, 2025 at 08:00 AM UTC

Supplementary Source Documents

Haili Biotech's Response to the Shanghai Stock Exchange's "Information Disclosure Regulatory Inquiry Letter Regarding the 2024 Annual Report of Shanghai Haili Biotechnology Co., Ltd."June 27, 2025 at 08:00 AM UTC

Shanghai Hile Bio-Technology

SSE:603718•Shanghai Stock Exchange

Animal Health

RSS feed for Shanghai Hile Bio-Technology

News Alerts

Get instant email alerts when Shanghai Hile Bio-Technology publishes news

Free account required • Unsubscribe anytime

Browse RSS Feeds

Filing Activity Timeline

View Complete Filing History →